Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Combivent Respimat

Known as: Respimat, Combivent 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Background Patients with chronic obstructive pulmonary disease (COPD) show signs of reduced physical activity from the early… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2018
2018
The INHALATOR study was a randomized, multicentre, open label, two-period of 7 days each, crossover study, with 7 days of washout… Expand
Is this relevant?
2018
2018
BACKGROUND When characterizing inhalation products, a comprehensive assessment including in vitro, pharmacokinetic (PK), and… Expand
Is this relevant?
2018
2018
Abstract The effectiveness of the tiotropium Respimat® formulation in routine clinical practice is still an open issue due to… Expand
Is this relevant?
2016
2016
AIM Two inhaler devices (Respimat® and HandiHaler®) are available for tiotropium, a long acting anticholinergic agent. We aimed… Expand
  • table 1
  • table 1
  • figure 1
  • table 2
Is this relevant?
2015
2015
Objectives: Hospital readmission has been an important issue in patients with chronic obstructive pulmonary disease (COPD), as it… Expand
Is this relevant?
2015
2015
 
Is this relevant?
2005
2005
IntroductionIn addition to offering favorable pharmaceutical performance, an ideal inhaler should be well accepted by patients… Expand
Is this relevant?
2004
2004
ObjectiveRespimat® Soft Mist™ Inhaler (SMI) is a novel, propellant-free device that significantly increases lung deposition… Expand
Is this relevant?